3.255

1.87% 0.055

Perspective Therapeutics Inc (CATX)

Overview News Price History Discussions Forecast Stock Split

Perspective Therapeutics Inc stock is traded at $3.255, with a volume of 630.00K. It is up +1.87% in the last 24 hours and up +9.03% over the past month. Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.

Previous Close:

$3.20

Open:

$3.21

24h Volume:

630.00K

Relative Volume:

0.39

Market Cap:

$371.56M

Revenue:

$618.00K

Net Income/Loss:

$-111.65M

P/E Ratio:

-2.3317

EPS:

-1.396

Net Cash Flow:

$-107.53M

1W Performance:

+8.67%

1M Performance:

+9.03%

6M Performance:

-32.78%

1Y Performance:

-9.70%

1-Day Range:

$3.19

$3.305

1-Week Range:

$2.9938

$3.305

52-Week Range:

$1.955

$6.16

Perspective Therapeutics Inc Stock (CATX) Company Profile

Name

Perspective Therapeutics Inc

Sector

Healthcare (1089)

Industry

Medical Devices (141)

Phone

509-375-1202

Address

350 Hills Street, Suite 106, Richland

Employee

Twitter

Next Earnings Date

2026-08-12

Latest SEC Filings

CATX's Discussions on Twitter

Compare CATX vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CATX Perspective Therapeutics Inc	3.255	365.29M	618.00K	-111.65M	-107.53M	-1.396
ABT Abbott Laboratories	110.11	192.51B	46.59B	5.41B	7.38B	3.0938
SYK Stryker Corp	332.33	130.11B	25.27B	3.34B	4.57B	8.6334
MDT Medtronic Plc	90.67	116.83B	36.36B	4.84B	5.43B	3.7261
BSX Boston Scientific Corp	51.55	75.11B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	90.83	52.80B	6.30B	1.07B	1.09B	1.8406

Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-19-26	Initiated	Piper Sandler	Overweight
Nov-24-25	Resumed	Truist	Buy
Oct-10-25	Initiated	BTIG Research	Buy
Mar-13-25	Initiated	H.C. Wainwright	Buy
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Nov-25-24	Downgrade	BofA Securities	Buy → Neutral
Oct-24-24	Initiated	UBS	Buy
Oct-01-24	Initiated	Wedbush	Outperform
Sep-25-24	Initiated	Truist	Buy
Jul-25-24	Initiated	BofA Securities	Buy
May-09-24	Initiated	Cantor Fitzgerald	Overweight

View All

Perspective Therapeutics Inc Stock (CATX) Latest News

Aug 14, 2026

CATX Maintained by B of A Securities -- Price Target Lowered to $5.00 - GuruFocus

Aug 14, 2026

Bank of America Lowers Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target to $5.00 - MarketBeat

Aug 14, 2026

Q3 EPS Forecast for Perspective Therapeutics Lifted by Analyst - MarketBeat

Aug 14, 2026

BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6 - marketscreener.com

Aug 14, 2026

Dimensional Fund Advisors LP Acquires 358,540 Shares of Perspective Therapeutics, Inc. $CATX - MarketBeat

Aug 14, 2026

Perspective Therapeutics (CATX) Stock Price, News & Analysis - marketbeat.com

Aug 14, 2026

Aug 13, 2026

Perspective Therapeutics (CATX): Millennium group reports over 5% beneficial stake - Stock Titan

Aug 13, 2026

Analysts Set Expectations for Perspective Therapeutics Q1 Earnings - MarketBeat

Aug 13, 2026

Aug 12, 2026

RBC Capital Sticks to Their Buy Rating for Perspective Therapeutics (CATX) - The Globe and Mail

Aug 12, 2026

Analysts Offer Insights on Healthcare Companies: Atossa Therapeutics (ATOS), Corvus Pharmaceuticals (CRVS) and Perspective Therapeutics (CATX) - The Globe and Mail

Aug 12, 2026